Navigation Links
Angioplasty may be feasible for liver transplantation candidates with heart disease
Date:6/22/2011

A small, retrospective study determined that percutaneous coronary intervention (PCI) was safe in patients with significant coronary artery disease (CAD) who were referred for liver transplantation. Larger studies are needed to determine the effectiveness of angioplasty in patients with end-stage liver disease (ESLD). Details of the study are available in the July issue of Liver Transplantation, published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

Medical evidence states that ESLD is associated with increased cardiovascular risk and CAD has been reported in up to 28% of this patient population, with those 50 years of age having the highest prevalence. Further studies have found that despite medical management or surgical revascularization, the three-year mortality of patients with CAD who receive liver transplants is 26% to 50%. Moreover, heart bypass surgery prior to transplantation can exacerbate liver failure and increase mortality risk.

"Our research is the first to demonstrate the feasibility and safety of PCI in patients with ESLD and thrombocytopenia who are candidates for liver transplantation," said Babak Azarbal, MD, interventional cardiologist at Cedars-Sinai Medical Center and lead author. In the past, PCI with stenting had not been used in patients with ESLD due to increased bleeding complications from peri- and post-procedural regimens that reduce the possibility of blood clots. These required anticoagulation and anti-platelet therapies could increase risk in ESLD patients with low platelets (thrombocytopenia) and bleeding disorders (coagulopathy).

The current study included 16 patients with ESLD who had significant CAD, but were acceptable candidates for liver transplantation. Fifteen patients underwent PCI using bare-metal stents and one patient had balloon angioplasty alone. Successful PCI was achieved in 94% of patients, with a single case of suboptimal residual stenosis following stenting. All patients remained clinically stable at one month following the intervention, with 9 patients added to the waiting list for liver transplantation and 3 who received liver transplants.

This research found PCI to be a safe and feasible option for ESLD patients with significant heart disease. Given the small sample size and retrospective nature of this study, the authors caution that their results may not be representative of the broader population of patients with ESLD and CAD. "Further investigation is needed to determine whether PCI improves clinical outcomes in ESLD patients with significant heart disease who otherwise would not be candidates for liver transplantation," concluded Antoine Hage, MD, Director of Solid Organ Transplant Cardiology at Cedars-Sinai Heart Institute in Beverly Hills, California and co-author of the study.


'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Cardiac Rehab Can Boost Survival After Angioplasty, Study Finds
2. Elevated protein levels in cardiac muscles could predict mortality following angioplasty
3. Many Heart Patients Place False Hope in Angioplasty
4. Drug trial results refine treatment during angioplasty operations
5. The Mount Sinai Hospital Earns Highest Ratings in New York State Report on Coronary Angioplasty
6. UCLA study compares bypass surgery to angioplasty
7. New Insights Into Whos At Risk With Angioplasty
8. NEJM Publishes Trial Results Demonstrating Bard FLAIR Endovascular Stent Graft Is Superior To Balloon Angioplasty For Failing Dialysis Grafts
9. Halving the radiation dose in cardiac perfusion imaging is now feasible
10. Baby-led weaning is feasible but could cause nutritional problems for minority of infants
11. Nanoparticles disguised as red blood cells will deliver cancer-fighting drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening to conquer ... in advanced audiology and hearing aid technology, has today ... world,s first internet connected hearing aid that opens up ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... , TwinLink™ - the first dual communication ...
(Date:6/23/2016)... Research and Markets has announced ... Analysis (United States, China, Japan, Brazil, United Kingdom, Germany, ... offering. Surgical Procedure ... planners, provides surgical procedure volume data in a geographic ... in-depth analysis of growth drivers and inhibitors, including world ...
(Date:6/23/2016)...  The National Pharmaceutical Council (NPC) today announced ... research organization as its newest member.  ... president and chief scientific officer, Mallinckrodt Pharmaceuticals, will ... Board of Directors. ... us in support of our efforts to conduct ...
Breaking Medicine Technology: